HDAC inhibitors induce transcriptional repression of high copy number genes in breast cancer through elongation blockade
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Treatment with histone deacetylase inhibitors (HDACI) results in potent cytotoxicity of a variety of cancer cell types, and these drugs are used clinically to treat hematological tumors. They are known to repress the transcription of ERBB2 and many other oncogenes, but little is known about this mechanism. Using global run-on sequencing (GRO-seq) to measure nascent transcription, we find that HDACI cause transcriptional repression by blocking RNA polymerase II elongation. Our data show that HDACI preferentially repress the transcription of highly expressed genes as well as high copy number genes in HER2+ breast cancer genomes. In contrast, genes that are activated by HDACI are moderately expressed. We analyzed gene copy number in combination with microarray and GRO-seq analysis of expression level, in normal and breast cancer cells to show that high copy number genes are more likely to be repressed by HDACI than non-amplified genes. The inhibition of transcription of amplified oncogenes, which promote survival and proliferation of cancer cells, might explain the cancer-specific lethality of HDACI, and may represent a general therapeutic strategy for cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040 · cited 1×
“Histone acetylation is associated with active transcription, so HDACI are believed to function by derepressing silent genes through the inhibition of HDAC activities found within many transcription corepressor complexes (7, 8).”
The complex language of chromatin regulation during transcription
Berger, S. L. (2007) · Nature · doi:10.1038/nature05915 · Cited by 2,768 · cited 1×
“Histone acetylation is associated with active transcription, so HDACI are believed to function by derepressing silent genes through the inhibition of HDAC activities found within many transcription corepressor complexes (7, 8).”
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Zuber, J., Shi, J., Wang, E., Rappaport, A. R., Herrmann, H., Sison, E. A., Magoon, D., Qi, J., Blatt, K., Wunderlich, M., et al. (2011) · Nature · doi:10.1038/nature10334 · Cited by 1,870 · cited 1×
“Also, a new class of cancer drugs (JQ1 and I-BET) that inhibit bromodomain containing protein 4 (BRD4), an acetyllysine binding protein that helps recruit P-TEFb, have shown great promise as a cancer therapy in several cancer types (24, 35, 36).”
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes
Wang, Z., Zang, C., Cui, K., Schones, D. E., Barski, A., Peng, W., & Zhao, K. (2009) · Cell · doi:10.1016/j.cell.2009.06.049 · Cited by 1,344
Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors
Khan, N., Jeffers, M., Kumar, S., Hackett, C., Boldog, F., Khramtsov, N., Qian, X., Mills, E., Berghs, S. C., Carey, N., et al. (2008) · Biochemical Journal · doi:10.1042/bj20070779 · Cited by 713
HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications
Khan, O., & La Thangue, N. B. (2012) · Immunology & Cell Biology · doi:10.1038/icb.2011.100 · Cited by 450 · cited 1×
“Their anti-cancer activities include inducing differentiation, cell cycle arrest and apoptosis, and decreasing angiogenesis (3, 4).”
Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution
Sollars, V., Lu, X., Xiao, L., Wang, X., Garfinkel, M. D., & Ruden, D. M. (2003) · Nature Genetics · doi:10.1038/ng1067 · Cited by 409 · cited 3×
“Moreover, it was recently found that Hsp90 is involved in maintaining a barrier to elongation.”
Influential
Cited by
Cancer transcriptome profiling at the juncture of clinical translation
Cieślik, M., & Chinnaiyan, A. M. (2018) · Nature Reviews Genetics · doi:10.1038/nrg.2017.96 · Cited by 269
Fuchs, G., Voichek, Y., Benjamin, S., Gilad, S., Amit, I., & Oren, M. (2014) · Genome Biology · doi:10.1186/gb-2014-15-5-r69 · Cited by 203
Histone Deacetylases Positively Regulate Transcription through the Elongation Machinery
Greer, C. B., Tanaka, Y., Kim, Y. J., Xie, P., Zhang, M. Q., Park, I.-H., & Kim, T. H. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.10.013 · Cited by 174
“The genes common to these categorized lists from the GRO-seq prepared for this manuscript, and the GRO-seq prepared previously (Kim et al., 2013) were used to analyze ChIP-seq data (Table S1).”
InfluentialSelf-citationCaslini, C., Hong, S., Ban, Y. J., Chen, X. S., & Ince, T. A. (2019) · Oncogene · doi:10.1038/s41388-019-0897-0 · Cited by 121
Seo, J., Min, S. K., Park, H.-R., Kim, D. H., Kwon, M. J., Kim, L. S., & Ju, Y.-S. (2014) · Journal of Breast Cancer · doi:10.4048/jbc.2014.17.4.323 · Cited by 100
“Several studies have shown that HDACIs can significantly en hance trastuzumabinduced growth inhibition and apoptosis in erbB2overexpressing breast cancer cells, suggesting an associ ation between HER2 and HDACs [10,11,19].”
Background
Metadata
- Authors
- Kim, Y. J., Greer, C. B., Cecchini, K. R., Harris, L. N., Tuck, D. P., & Kim, T. H.
- Venue
- Oncogene
- Published
- 2013-02-25
- Volume
- 32
- Issue
- 23
- Pages
- 2828-2835
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W1969201755
- Cited by
- 95
- References
- 8
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.